AR053232A1 - CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM. - Google Patents

CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.

Info

Publication number
AR053232A1
AR053232A1 ARP060101551A ARP060101551A AR053232A1 AR 053232 A1 AR053232 A1 AR 053232A1 AR P060101551 A ARP060101551 A AR P060101551A AR P060101551 A ARP060101551 A AR P060101551A AR 053232 A1 AR053232 A1 AR 053232A1
Authority
AR
Argentina
Prior art keywords
group
heteroaryl
aryl
diseases related
therapeutic agents
Prior art date
Application number
ARP060101551A
Other languages
Spanish (es)
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of AR053232A1 publication Critical patent/AR053232A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de piridina que tienen efecto inhibitorio de la síntesis de citoquinas que están involucradas en reacciones inflamatorias, y que por lo tanto son utiles como agentes terapéuticos para el tratamiento de enfermedades relacionadas con la inflamacion, enfermedades relacionadas con el sistema inmune y enfermedades inflamatorias cronicas. Métodos y un agente antiinflamatorio y analgésico, y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto representado por la formula (1), o sus sales aceptables para uso farmacéutico, donde R1, R2, R3, R4 y R5 se pueden seleccionar independientemente del grupo que consiste en H, halo, ciano, nitro, acilo, hidroxi, amino, alquilo bajo C1-6, alquenilo bajo C2-6, alcoxilo bajo C1-6, alquiltio C1-6, alquilamino C1-10, cicloalquilamino C4-9, heterocicloalquilamino C4-9, arilamino, acilamino, aciloxilo, alquilsulfinilo C1-6, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, arilsulfinilo, arilsulfonilo, arilsulfonilamino, arilo, heteroarilo, aralquilo C1-10, heteroaralquilo C1-10, ariloxilo y heteroariloxilo, o pueden formar independientemente un anillo mediante union con un grupo de sustitucion vecino; X es O o S; Y es O o N-R6, donde R6 del grupo que consiste en H, alquilo bajo C1-6, acilo, arilo, heteroarilo, aralquilo C1-10 y heteroaralquilo C1-10; o pueden formar independientemente un anillo mediante union con un grupo de sustitucion vecino R5; dicho arilo se elige del grupo que consiste en fenilo, naftilo y fenilo fusionado; dicho heteroarilo es u anillo heterocíclico de 5 miembros o de 6 miembros, o un anillo heterocíclico fusionado que tiene entre 1 y 3 heteroátomos seleccionados de entre O, N y S; dicho arilo y heteroarilo pueden estar sustituidos con 1 a 4 grupos sustituyentes seleccionados del grupo que consiste en halo, hidroxi, alquilo bajo C1-6, alcoxilo bajo C1-6 y amino.Pyridine derivatives that have an inhibitory effect on the synthesis of cytokines that are involved in inflammatory reactions, and that are therefore useful as therapeutic agents for the treatment of diseases related to inflammation, diseases related to the immune system and chronic inflammatory diseases. Methods and an anti-inflammatory and analgesic agent, and pharmaceutical compositions containing them. Claim 1: A compound represented by formula (1), or its salts acceptable for pharmaceutical use, wherein R1, R2, R3, R4 and R5 can be independently selected from the group consisting of H, halo, cyano, nitro, acyl, hydroxy, amino, lower C1-6 alkyl, lower C2-6 alkenyl, lower C1-6 alkoxy, C1-6 alkylthio, C1-10 alkylamino, C4-9 cycloalkylamino, C4-9 heterocycloalkylamino, arylamino, acylamino, acyloxy, C1 alkylsulfinyl -6, C1-6 alkylsulfonyl, C1-6 alkylsulfonylamino, arylsulfinyl, arylsulfonyl, arylsulfonylamino, aryl, heteroaryl, C1-10 aralkyl, C1-10 heteroaralkyl, aryloxy and heteroaryloxy groups, or can independently form a ring by joining with a substitution group neighbour; X is O or S; Y is O or N-R6, where R6 of the group consisting of H, C1-6 lower alkyl, acyl, aryl, heteroaryl, C1-10 aralkyl and C1-10 heteroaralkyl; or they can independently form a ring by joining with a neighboring substitution group R5; said aryl is selected from the group consisting of phenyl, naphthyl and fused phenyl; said heteroaryl is a 5-membered or 6-membered heterocyclic ring, or a fused heterocyclic ring having between 1 and 3 heteroatoms selected from O, N and S; said aryl and heteroaryl may be substituted with 1 to 4 substituent groups selected from the group consisting of halo, hydroxy, C1-6 lower alkyl, C1-6 lower alkoxy and amino.

ARP060101551A 2005-04-20 2006-04-19 CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM. AR053232A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20050032888 2005-04-20

Publications (1)

Publication Number Publication Date
AR053232A1 true AR053232A1 (en) 2007-04-25

Family

ID=37115350

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101551A AR053232A1 (en) 2005-04-20 2006-04-19 CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.

Country Status (3)

Country Link
KR (1) KR100781704B1 (en)
AR (1) AR053232A1 (en)
WO (1) WO2006112666A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (en) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
CN102124009B (en) 2008-07-08 2014-07-23 因特利凯公司 Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
US8722692B2 (en) 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CN103930422A (en) 2011-07-19 2014-07-16 无限药品股份有限公司 Heterocyclic compounds and uses thereof
JP6027611B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (en) 2011-09-02 2020-01-08 Univ California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof.
EP2809322B9 (en) 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN104520297B (en) * 2012-08-13 2016-08-24 瑞士诺华动物保健有限公司 Bicyclic heteroaryl cycloalkyl diamine derivative as kidney tyrosine kinase inhibitor
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EA035095B1 (en) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Bicyclic heterocycles as fgfr inhibitors
JP6466924B2 (en) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3640241T3 (en) 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Bromodomain inhibitors
DK3119397T3 (en) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (en) 2015-02-20 2017-10-23 Incyte Holdings Corp BICYCLE HETEROCICLES AS FGFR INHIBITORS
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
AR104259A1 (en) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc BROMODOMINUM INHIBITORS
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2019513804A (en) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (en) 2019-10-14 2022-10-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220138654A (en) * 2021-04-06 2022-10-13 주식회사 온코크로스 Compound for preventing or treating diabetes mellitus
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023129933A2 (en) * 2021-12-29 2023-07-06 858 Therapeutics, Inc. 6,6-fused heterocyclic compounds as mettl3 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (en) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JPH08337583A (en) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd Heterocyclic compound and its production
JP2001031679A (en) * 1998-08-26 2001-02-06 Tanabe Seiyaku Co Ltd Naphthyridine derivative and its production
WO2000032192A1 (en) * 1998-11-27 2000-06-08 Takeda Chemical Industries, Ltd. Drugs
AU2001286188A1 (en) * 2000-09-11 2002-03-26 Takeda Chemical Industries Ltd. Tricyclic heterocyclic compound, process for producing the same, and use thereof
WO2002074771A1 (en) * 2001-03-19 2002-09-26 Takeda Chemical Industries, Ltd. Tricyclic heterocyclic compound, process for producing the same, and use
WO2005026166A1 (en) * 2003-09-16 2005-03-24 'chemical Diversity Research Institute', Ltd. Physiologically active composition, pharmaceutical composition, substituted 1,2-dihydro[2,7] naphthyridines, method for the production and use thereof

Also Published As

Publication number Publication date
WO2006112666A1 (en) 2006-10-26
KR100781704B1 (en) 2007-12-03
KR20060110764A (en) 2006-10-25

Similar Documents

Publication Publication Date Title
AR053232A1 (en) CONDENSED PIRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF ANTI-INFLAMMATORY THERAPEUTIC AGENTS AND FOR THE TREATMENT OF DISEASES RELATED TO THE IMMUNOLOGICAL SYSTEM.
PE20220931A1 (en) PYRAZOLO[3,4-B]PYRAZINE-TYPE SHP2 PHOSPHATASE INHIBITORS
DOP2022000278A (en) CYSTEINE PROTEASE INHIBITORS AND THEIR METHODS OF USE
AR048427A1 (en) DERIVATIVES OF SULFONILPIRROLES WITH INHIBITORY ACTIVITY OF HISTONE DEACETILASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE SAME FOR THE TREATMENT OF RELATED DISEASES.
AR055057A1 (en) HETEROCICLIC INHIBITORS OF MEK, CRYSTAL FORMS OF THE SAME, PROCESSES FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER OR OF AN INFLAMMATORY CONDITION.
AR043038A1 (en) PIRAZOLOTRIAZINE COMPOUNDS AND USES OF THE SAME
CY1124913T1 (en) N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
AR049711A1 (en) HETEROCICLIC COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONE SINTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO HYPERALDOSTERISM AND EXCESSIVE CORTISO RELEASE
AR039648A1 (en) USED ARIL CETONA PIRROLO TRIAZINA COMPOUNDS AS KINASE INHIBITORS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR030553A1 (en) USE OF DERIVATIVES OF TIAZOLILO 2,4-DISPOSED FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF DISEASES MEDIATION THROUGH CYTOKINES, DERIVATIVES OF TIAZOLYLL 2,4-DISPOSED, PHARMACEUTICAL COMPOSITIONS THAT THEY UNDERTAKED
AR016762A1 (en) 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME
AR063602A1 (en) DERIVATIVES OF SPIROINDOLINONE, PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM AND THEIR USE IN THE OBTAINING OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ONCOLOGICAL DISORDERS.
AR066583A1 (en) DERIVATIVES OF 3,3-ESPIROINDOLINONA
AR063458A1 (en) INHIBITING PIRIDINE DERIVATIVES OF 11BETA HSD1
ATE402174T1 (en) IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS
UY29393A1 (en) NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
AR029301A1 (en) COMPOUNDS DERIVED FROM BIARILO, METHODS FOR THEIR PREPARATION COMPOSITIONS THAT CONTAIN THEM, THEIR USE AS AGONISTS IN BETA-ADRENO-ATIPIC RECEIVERS
HUP0402352A2 (en) Pyrimidine derivatives for use as phosphodiesterase (pde)7 inhibitors and pharmaceutical compositions containing them
AR058769A1 (en) PEPTIDIL DEFORMILASE INHIBITORS (PDF), USEFUL FOR THE TREATMENT OF TUBERCULOSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR927003052A (en) 2-arylthiazole derivatives and pharmaceutical compositions thereof
AR044078A1 (en) SUBSTITUTED DIHYDROQUINAZOLINS
MX2010000658A (en) Pyrimidine derivatives 934.
AR039256A1 (en) DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS
AR069813A1 (en) DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT
AR056645A1 (en) UREA COMPOUNDS REPLACED INHIBITORS OF ENZYMES CHK1.

Legal Events

Date Code Title Description
FB Suspension of granting procedure